b1f01324-d0ca-4779-9ae0-5348e2613084
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.300
- COAGULATION+0.200
- MYOGENESIS+0.200
- PANCREAS_BETA_CELLS+0.200
- ALLOGRAFT_REJECTION+0.100
- APICAL_JUNCTION+0.100
- APICAL_SURFACE+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
- SPERMATOGENESIS+0.100
- XENOBIOTIC_METABOLISM+0.100
Top 10 suppressed
- G2M_CHECKPOINT-0.600
- ANDROGEN_RESPONSE-0.500
- E2F_TARGETS-0.500
- MITOTIC_SPINDLE-0.500
- MTORC1_SIGNALING-0.500
- MYC_TARGETS_V1-0.500
- PROTEIN_SECRETION-0.500
- TGF_BETA_SIGNALING-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD014_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.903 |
| 2 | MNG1159 | — | — | 0.891 |
| 3 | TCGA-E7-A519-01A-11R-A26T-07 | — | — | 0.876 |
| 4 | SRR1472663 | GTEX | — | 0.874 |
| 5 | SRR1797260 | — | cohortSC | 0.874 |
| 6 | TCGA-49-AAR2-01A-11R-A39D-07 | — | cohortA3 | 0.872 |
| 7 | SRR1473654 | GTEX | — | 0.872 |
| 8 | BS_0BXY0F9N | EPN | Posterior Fossa EPN | 0.871 |
| 9 | SRR1332048 | GTEX | — | 0.869 |
| 10 | MNG1245 | — | — | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.100 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |